Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland, Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-ov ...

BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders. "As a research and teaching hospital, as well as a clinical center of excellence, it is our goal to ...

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its oncology testing capabilities through advanced liquid biopsy solutions [1][4] - The partnership with SOPHiA GENETICS aims to leverage cutting-edge technology for rapid validation of genomic panels and sequencing, supporting OncoHelix's mission in precision oncology [3][4] Company Overview - OncoHelix, based in Calgary, Canada, specializes in genomic and molecular testing services globally and collaborates with the Hematology Translational Lab at the University of Calgary [2] - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine, providing the SOPHiA DDM™ platform for analyzing complex genomic data [6] Technology and Innovation - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, analyzing 146 key cancer-associated genes [4] - Liquid biopsy testing offers a less invasive alternative to traditional solid tumor biopsies, extracting cell-free DNA from blood plasma to reveal circulating tumor DNA [3]

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its genomic and molecular testing capabilities [1][8] - The partnership with the Hematology Translational Lab at the University of Calgary has significantly advanced precision oncology and immunology research [1] - Liquid biopsy testing, which extracts cell-free DNA from blood plasma, offers a less invasive alternative to traditional biopsies, facilitating quicker clinical decisions and monitoring [2][9] Company Developments - OncoHelix will utilize the new liquid biopsy solution to enhance its oncology testing capabilities, building on its existing use of the SOPHiA DDM™ Platform for myeloid testing [8][9] - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, focusing on deep sequencing of 146 cancer-associated genes [9] - The implementation of this technology is expected to improve the assessment of cancer treatment responses and the diagnosis of cases where tissue biopsy is not feasible [3][9] Industry Context - SOPHiA GENETICS is a leader in data-driven medicine, utilizing AI to provide actionable insights for healthcare institutions globally [5] - The collaboration between OncoHelix and SOPHiA GENETICS reflects a growing trend in the healthcare industry towards integrating advanced genomic technologies to improve patient care [9]

Company Overview - SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, utilizing AI to enhance patient care for cancer and rare disorders globally [3] - The company developed the SOPHiA DDM™ Platform, which analyzes complex multimodal data to provide real-time, actionable insights for hospitals, laboratories, and biopharma institutions [3] Financial Results Announcement - SOPHiA GENETICS will release its financial results for Q2 of fiscal year 2024 before U.S. markets open on August 6, 2024 [1] - A conference call to discuss the financial results and business outlook will take place at 8:00 a.m. EDT / 2:00 p.m. CET on the same day [1] Investor Relations - The conference call will be available via live webcast on the SOPHiA GENETICS Investor Relations Website, with a replay accessible after the event [2]

Core Viewpoint - SOPHiA GENETICS held its annual general meeting of shareholders, where all proposals were adopted, reflecting strong shareholder support [1][5]. Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on expanding access to data-driven medicine using AI to provide care for patients with cancer and rare disorders globally [6]. - The company has developed SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions [6]. Shareholder Engagement - The company expressed gratitude to shareholders for their votes and commitment, indicating a positive relationship with its investor base [3]. - Detailed voting results from the AGM will be published on the company's website and filed with the U.S. Securities and Exchange Commission [5].

Core Viewpoint - SOPHiA GENETICS has launched a new Residual Acute Myeloid (RAM) Application to enhance measurable residual disease (MRD) testing, aimed at improving cancer monitoring and relapse prevention [1][2] Group 1: Product Features and Capabilities - The SOPHiA DDM™ RAM Solution utilizes next-generation sequencing (NGS) for MRD testing, capable of detecting one cancer cell among 10,000 cells, with a variant allele frequency (VAF) sensitivity down to 0.01% [2] - The application supports longitudinal variant monitoring, allowing visualization of the mutational landscape for each patient over time, and includes customizable reporting features for comprehensive MRD reports [8] - The solution will continuously improve its machine learning algorithms to provide accurate MRD results within four days [9] Group 2: Market Context and Importance - Acute Myeloid Leukemia (AML) accounts for about 1% of all cancers globally and has a high relapse rate, with over 50% of patients relapsing within three years of achieving complete remission [6] - MRD solutions are critical for informing post-remission therapy and detecting early relapse, serving as a primary endpoint in clinical trials to enhance patient outcomes [6][7] - The introduction of the RAM Solution addresses a significant unmet medical need in AML treatment, potentially transforming clinical research through improved tracking of individual mutations over time [7]

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of further ...

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole genome sequencing (WGS) analytical solution ...

Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine and is a leader in the field [5] - The company has developed the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to provide actionable insights for hospitals, laboratories, and biopharma institutions globally [5] Industry Context - Cancer is the second most common cause of death in Brazil, with an estimated 704,000 new cancer cases expected between 2023 and 2025 [2] - Blood cancers rank as the fifth most common type of cancer worldwide [2] - Instituto Mário Penna, a major oncology service provider in Brazil, has implemented the SOPHiA DDM™ Platform to enhance its testing capabilities and improve data-driven treatment plans for blood-related cancers [2][3] Technological Advancements - The SOPHiA DDM™ Platform utilizes next-generation sequencing (NGS) to identify key variants from various sample types, facilitating rapid and accurate detection of disease-associated variants [3] - The platform is designed to compute a wide array of genomic variants and continuously improves its machine learning algorithms for better detection of rare and challenging cases [4] - Results from the SOPHiA DDM™ Platform are nearly 100 percent reproducible, ensuring consistent and reliable sequencing data [4]